Intraosseous Antibiotics for Joint Infections
Trial Summary
What is the purpose of this trial?
Purpose of Study: In order to improve upon the variable results seen in irrigation and debridement for periprosthetic infection, we ask if the use of intraosseous regional administration of antibiotics at the time of irrigation and debridement will improve the modest success of standard irrigation and debridement. We will use the existing literature on standard irrigation and debridement procedures to compare with the results of the irrigation and debridement with the use of intraosseous antibiotics. Impact Question: How will this study benefit the patient? Currently when an I\&D fails, the patient needs to undergo two more major procedures: 1) implant removal and 2) reimplantation of the prosthesis. Any improvement in the results of a standard irrigation and debridement procedure may decrease the number of patients having to go through further extensive procedures to cure their infection.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug Intraoperative Intraosseous Vancomycin for joint infections?
Is intraosseous vancomycin safe for use in humans?
How does intraosseous antibiotic treatment differ from other treatments for joint infections?
Intraosseous antibiotic treatment is unique because it delivers antibiotics directly into the bone, achieving higher local concentrations and reducing systemic side effects compared to traditional intravenous methods. This approach is particularly effective in preventing infections after surgeries like total knee arthroplasty, where it can provide better protection against resistant bacteria.12379
Research Team
Thomas K. Fehring, MD
Principal Investigator
OrthoCarolina Research Institute, Inc.
Eligibility Criteria
This trial is for adults over 18 with a knee joint infection after surgery, within the first 90 days or with symptoms under four weeks. It includes those who can't have their prosthetic knee removed due to complex implants and whose infections are treatable by vancomycin. Excluded are individuals with severe kidney disease, known allergy to vancomycin, pregnant women, and cases where the infecting organism is unknown or resistant to vancomycin.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo irrigation and debridement with intraosseous vancomycin and receive at least 4 weeks of IV antibiotics
Follow-up
Participants are monitored for recurrence of infection and effectiveness of treatment
Treatment Details
Interventions
- Intraoperative Intraosseous Vancomycin
Find a Clinic Near You
Who Is Running the Clinical Trial?
OrthoCarolina Research Institute, Inc.
Lead Sponsor
American Association of Hip and Knee Surgeons
Collaborator
American Association of Hip and Knee Surgeons
Collaborator